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CD8+ T cells play important roles in immunity and immuno-oncology. Upon antigen
recognition and co-stimulation, naïve CD8+ T cells escape from dormancy to engage in
a complex programme of cellular growth, cell cycle entry and differentiation, resulting in
rapid proliferation cycles that has the net effect of producing clonally expanded, antigen-
specific cytotoxic T lymphocytes (CTLs). A fraction of activated T cells will re-enter
dormancy by differentiating into memory T cells, which have essential roles in adaptive
immunity. In this review, we discuss the current understanding of cell cycle entry control
in CD8+ T cells and crosstalk between these mechanisms and pathways regulating
immunological phenotypes.
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INTRODUCTION
CD8+ T cells are an important component of the acquired immune response. They have a role in
limiting viral infection and cancer progression through recognising key viral/tumour antigens on
the infected cell surface and targeting them for destruction (Kim and Ahmed, 2010). T cells are
the product of central selection, a process in which newly developed progenitor T cells go through
differentiation and numerous divisions, becoming lineage restricted toward the naïve CD8+ T cell
phenotype. These naive T cells then lie dormant predominately within the lymph nodes (Carpenter
and Bosselut, 2010). Naïve CD8+ T cells are activated by antigen presenting cells. The activation
phase is characterised by major rewiring of their cellular proteomes and metabolism. Activated
T cells then rapidly proliferate in what is known as the expansion phase (Figure 1A). During this
phase, the doubling rate averages at 6–8 h with some studies demonstrating a peak doubling time of
4.5 h, or even 2 h (Kurts et al., 1997; Yoon et al., 2010). Also during this phase, T cells will begin to
differentiate toward one of two T effector (Teff ) phenotypes, the short lived effector cell (SLEC)
which die during the subsequent contraction phase, and the memory progenitor cells (MPEC)
which survive beyond the contraction phase. MPECs then differentiate toward one of the memory
T cell phenotypes, e.g., the central memory T cell (Tcm), and effector memory T cell (Tem). The
role of SLECs is to clear the infection, which is done by targeted release of cytolytic granzymes and
perforins to infected cells. Following the clearance of infection, memory T cells remain in a state
of dormancy, with Tcm localising to the lymph nodes, and Tem remaining in the periphery. Like
naïve T cells, they await antigen stimulation in order to activate and proliferate, but have a higher
antigenic threshold and more quickly initiate proliferation (Mehlhop-Williams and Bevan, 2014).
This enables memory T cells to act as early responders to repeat infections.
What factors determine whether daughter cells from an activated naïve T cell move toward the
MPEC or SLEC phenotype are a topic of active debate. It is generally agreed, however, that SLECs
represent a fully differentiated form of T cell, which develop full effector function in exchange of
proliferative potential and survival that typify MPECS. Complementing this model are studies that
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demonstrate differences in cell cycle progression between
the phenotypes, with SLECs progressing at a much faster
rate than MPEC (Kinjyo et al., 2015; Kretschmer et al.,
2020) demonstrating a link between control of proliferation
and differentiation.
In this review, we will first present an overview on cell cycle
regulation based on various mammalian model systems. We then
examine the pathways controlling CD8+ T cell differentiation
and proliferation with reference to the cell cycle regulation
pathways outlined prior and explore potential crosstalk between
these two key processes.
CELL CYCLE REGULATION
The cell cycle is divided into four phases (Figure 1B). In the
first gap phase (G1), the cell prepares for DNA replication
(S). This is followed by a second gap phase (G2) when the
cell prepares for mitosis (M). Quiescent, or G0 cells enter the
cell cycle by first transiting through G1. During G1, cells pass
through a commitment step called the restriction point (R).
Before R, cells are susceptible to cell cycle arrest by mitogen
starvation. However, beyond R, progression through the cell
cycle is mitogen-independent in human fibroblasts. The time
cells spend in pre-R G1 is heterogeneous compared with the
time spent in the remaining phases of the cell cycle (Zetterberg
and Larsson, 1985; Zetterberg et al., 1995). Additionally mitogen
starved cells which exit to G0 and are reintroduced to mitogen
have been observed to take up to an additional 8 h to reach
and complete mitosis compared to cells cultured in mitogen-
replete conditions (Zetterberg and Larsson, 1991). Thus, G0,
pre-R and post-R G1 can be considered distinct phases that
are distinguished in their mitogen responsiveness and in the
length of time needed to progress to S-phase. It should be
noted, however, that it is as yet unclear if the restriction point
as described in fibroblasts exists within T cells. This is due
to the differences in mitogenic signalling within T cells which
make the model established in fibroblasts more challenging to
test in T cells.
Key proteins that control cell cycle progression include (1) the
cyclin proteins, which rise and fall in abundance at key stages of
cell cycle, (2) the cyclin-dependent kinases (CDKs) which become
active when bound to their cognate cyclins, and (3) the CDK
inhibitor proteins (CDKi) which control cell cycle progression
at key check points in response to mitogen starvation or cellular
stress (e.g., DNA damage).
CDK-Rb-E2F
Cyclins, CDKs, and CDKis have key roles in regulating the
activity of E2 factor F (E2F), a transcription factor that promotes
the expression of cell cycle genes, including the cyclins and
CDKs themselves.
In G0 and pre-R G1, E2F mediated transcription will be
inhibited by pocket proteins Retinoblastoma protein (Rb), p107,
and p130, preventing the cell from progressing to S phase
(Stengel et al., 2009). An active kinase complex is formed by
interaction of cyclin D with either CDK4 or CDK6, and this
FIGURE 1 | The cell cycle can be split into four phases: the first gap phase
(G1), DNA synthesis phase (S), the second gap phase (G2), and mitosis (M).
G1 can be further subdivided into pre- and post- restriction point G1 (pre-R
G1, post-R G1). Quiescent cells are in a G0 state. (A) Naïve T cells are cells in
G0. Upon maximum stimulation by T-cell receptor-antigen and co-stimulation,
murine CD8+ T cells enter the cell cycle, going through only a few divisions
until they receive the IL-2 signal, at which point they proliferate rapidly as they
enter the expansion phase. (B) During activation, T cells enter an extended
G1 phase, in which cells increase in size by ∼3–4-fold, entering their first
S-phase within 30 h. During the expansion phase, cells then undergo rapid
proliferation, dividing as quickly as once every 4 h, to clonally expand the
antigen-specific T cell pool. Arrows indicate continuation beyond mitosis into
the next G1.
kinase activity mediates hyperphosphorylation of Rb, causing
Rb to decouple from E2F, and thereby enable E2F to promote
upregulation of its targets. Such targets include a large number
of S phase-promoting proteins, including cyclin E and cyclin
A. Cyclin E will form a complex with CDK2 which amongst
other processes will contribute to Rb hyperphosphorylation,
resulting in a positive feedback loop that activates E2F (Dyson,
1998). Recent work suggests that CDK4/6 regulates cellular
processes other than those downstream of E2F. Cyclin D3-
CDK6 phosphorylates key enzymes in the glycolysis pathway,
diverting metabolites from glycolysis into the pentose phosphate
pathway to promote redox balance (via production of NADPH)
and cellular anabolism (e.g., by generating nucleotide precursors)
(Wang et al., 2017).
Cyclin-dependent kinases activities can be inhibited by
stoichiometric binding to CDKis, of which there are two main
families: the INK4 family consisting of p16, p15, p18, and
p19 which inhibit Cyclin D-CDK4/6 complex; and the Cip/Kip
family which consists of p27, p21, and p57 that inhibit cyclin-
CDK complexes, and are able to induce cell cycle arrest at G1
phase (Sherr and Roberts, 1999). The regulation of CDK4/6
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complexes by the Cip/Kip family members are more complex.
Cip/Kip proteins can promote the formation of cyclin-CDK
complexes and in the absence of p21 or p27, cyclin D-CDK
complexes do not form (Labaer et al., 1997; Cheng et al., 1999).
Trimeric species containing p27 phosphorylated on tyrosine
74, cyclin D, and CDK4 retain kinase activity (Guiley et al.,
2019). On the other hand, high levels of p21 inhibit CDK4
(Labaer et al., 1997). Cip/Kip proteins are inactivated by
post-translational modification and degradation. For example,
tyrosine phosphorylation on p27 by mitogen-activated tyrosine
kinases disrupts the inhibitory interaction of p27 with CDK2 and
promotes p27 degradation (Grimmler et al., 2007),
Anaphase Promoting
Complex/Cyclosome
Stability of cyclin, CDK and CDKi proteins are controlled
post-translationally in a cell cycle regulated manner by E3
ubiquitin ligases. The anaphase promoting complex/cyclosome
(APC/C) is a large, multi-subunit E3 ligase that targets many
proteins, including cyclins and other E2F targets, for destruction
in mitosis and G1. The APC/C has two co-activators, Cell
Division Cycle (Cdc) 20 and Fizzy-related protein homolog-1
(Fzr1) (also known as Cdh1). The substrate adaptor functions
of Cdc20 are primarily in mitosis, whereas Cdh1 is important
in mitotic exit and G1. Indeed, inactivation of the APC/C-
Cdh1 has been shown to be a second crucial step in promoting
the transition from G1 to S (Cappell et al., 2016). Thus,
proteins required for G1/S are upregulated by increased synthesis
via transcription by E2F and increased stability via APC/C
inactivation. APC/C inactivation in G1 is mediated by multiple
mechanisms, including phosphorylation of Cdh1 (Kramer et al.,
2000) by CDK2 (Lukas et al., 1999) and by the accumulation the
pseudosubstrate inhibitor protein, F-box only protein 5 (Fbxo5)
[also known as the early mitotic inhibitor 1 (Emi1)] (Cappell
et al., 2018). Additionally, there are deubiquitinases (DUBs),
including ubiquitin specific peptidase 37 (Usp37), which stabilise
APC/C substrates by removing ubiquitin chains that would
otherwise target these proteins for proteasomal destruction
(Huang et al., 2011).
ACTIVATION PHASE (TCR INDUCED
PROLIFERATION)
T cell activation and proliferation requires three stimulation
signals, antigenic stimulation via the T cell receptor (TCR),
co-receptor signalling from professional antigen presenting
cells via CD28, and cytokine stimulation primarily driven by
interleukin (IL)-2. Stimulation of the TCR alone results in
anergy. Anergic cells do not produce IL-2, fail to proliferate, and
become unresponsive to further stimulation attempts. A dual
signal of TCR and CD28 induces production of IL-2 and
proliferation within the first 24 h. IL-2 stimulation through the
IL-2 receptor (IL-2R) enables rapid proliferation as the cells enter
the expansion phase (Mondino et al., 2006).
As depicted in Figure 2A, TCR stimulation leads to
phosphorylation of lymphocyte-specific protein tyrosine kinase
FIGURE 2 | Pathways in CD8+ T cells that contribute to the proliferation via
upregulation of E2F and pro-survival signals, or contribute toward
differentiation in both (A) antigen induced activation phase and (B) the IL-2
mediated expansion phase CD8+ T cells. P, phosphorylation. A detailed
description is provided in the main text.
(Lck), which in return phosphorylates the ζ chains of the
TCR along the immunoreceptor tyrosine-based activation motifs
(ITAMS). This enables recruitment of TCR-associated protein 70
(Zap70), which is subsequently phosphorylated by Lck. Zap70
then phosphorylates four key sites on the linker for activation of
T cells (LAT) which allows for recruitment of proteins into the
LAT signalosome. The downstream effect is activation of the Rat
sarcoma (Ras)/extracellular signal-related kinase (Erk)/Activator
protein 1 (AP-1) pathway, Protein kinase C–θ (PKCθ)/κB kinase
(IKK)/nuclear factor-κB (Nf-κB) pathway, and the calcium-
dependent Calcineurin/nuclear factor of activated T cells (NFAT)
pathway (Brownlie and Zamoyska, 2013; Hwang et al., 2020).
The transcription factors downstream of these pathways, NFAT,
Nf-κB, and AP-1 all contribute to the transcription of IL2 and
also contribute to the transcription of IL2RA, which encodes the
α-chain of the IL-2 receptor (CD25) (Liao et al., 2013).
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Protein tyrosine kinase positively regulates phosphoinositide-
dependent kinase 1 (PDK1) activity, which stimulates two
major pathways: PKCθ/IKK/Nf-κB pathway and the Ak strain
transforming (AKT)/ mammalian target of rapamycin complex
1 (mTORC1) pathway. Lck mediates this via activation of
phosphoinositide 3-Kinase (PI3K), which is enhanced by
co-receptor CD28 stimulation. PI3K is also responsible for
enabling the assembly of mTOR complex 2 (mTORC2), which
activates AKT, enabling it to target its substrates, such as the
mTORC1 inhibitor, Hamartin (TSC1)/Tuberin (TSC2), thereby
upregulating mTORC1 activity (Brownlie and Zamoyska, 2013;
Jutz et al., 2016; Spolski et al., 2018; Hwang et al., 2020).
With TCR stimulation alone, however, the components of the
LAT signalosome, as well as PKCθ are targeted for degradation
by the E3-Ubiquitin ligase casitas B-lineage lymphoma proto-
oncogene (Cbl)-b. Cbl-b also has the effect of reducing PI3K
activity by preventing formation of phosphatidylinositol-3-
phosphate (PIP3). The net effect of this is a sharp reduction
in NFAT, NFκB, AP-1, and mTOR activity, resulting in the cell
becoming anergic (Liu et al., 2014).
CD28 stimulation counteracts this effect by enhancing PKCθ
activity, which promotes degradation of Cbl-b. Indeed, loss
of PKCθ activity further decreases transcription factor activity
downstream of LAT (Gruber et al., 2009), while knockout of
CD28 leads to a reduction in proliferation (Li et al., 2004).
Conversely, both Cbl-b deletion and Cbl-b inactive mutation
enables T cell proliferation and production of IL-2 in the absence
of CD28 signal. Loss of Cbl-b activity greatly enhances CD28-
mediated proliferation and IL-2 production (Paolino et al., 2011).
Consistent with a role in negatively regulating activation, Cbl-
b also emerged as a top hit in a CRIPSR genetic screen for
regulators of secondary activation in human CD8+ T cells
(Shifrut et al., 2018).
Interestingly, there is no requirement for Lck in the activation
of memory T cells upon secondary infection by LCMV in vivo.
The frequency of antigen-specific T cells after secondary
challenge to antigen was unaffected in memory cells depleted of
Lck compared to Lck-replete cells, suggesting that proliferation
is unaffected by Lck depletion. Re-challenged Lck-depleted cells
also produced comparable levels of interferon (IFN)-γ to that
of Lck-replete cells. This is in direct contrast to naïve cells
depleted of Lck, which do not proliferate in response to antigen
(Tewari et al., 2006). In addition, ex vivo memory T cells seem
more reliant on cytokine signalling to induce proliferation, with
antigen and CD28 stimulation alone proving insufficient to
trigger proliferation in memory T cells (Cho et al., 1999).
Mammalian Target of Rapamycin
Complex, Cell Growth, and E2 Factor F
T cell receptor/CD28 stimulation of naïve cells is sufficient
to initiate proliferation. TCR/CD28 stimulation leads to
phosphorylation of Rb, expression of cyclin E, cyclin A, and
CDK2, and the degradation of p27 (Appleman et al., 2000).
Rapamycin, an inhibitor of mTOR, induces a severe delay
in proliferation (D’Souza and Lefrançois, 2003), resulting in
decreased levels of cyclin D3 and cyclin E. And while cyclin
D3 levels recover 3–5 days following rapamycin treatment,
cyclin E remains low, suggesting a dependence on mTOR
for antigen-induced E2F activation. Although the exact
mechanism is unknown, expression of a rapamycin resistant
mutant of p70S6k (also known as S6K) rescues E2F activity in
rapamycin-treated cells; thereby demonstrating that mTOR
activity promotes cell cycle progression by activating E2F
through S6K (Brennan et al., 1999). In contrast to wild-type
cells, proliferation of IL-2−/− cells is arrested completely by
rapamycin. In addition, stimulator of interferon genes (STING)
activity reduces levels of cyclins A and E, and Cdk1, leading
to a reduction in activation induced proliferation. STING
inhibits mTOR, reduces S6K activity, reduces phosphorylation
of eukaryotic translation initiation factor 4E (eIF4E)-binding
protein (4E-BP1), and reduces STAT5 phosphorylation,
leading to decreased levels of S-phase promoting proteins
(Imanishi et al., 2019). Together these results suggest that
IL-2 signalling contributes to proliferation in an mTOR-
independent manner as outlined in Figure 2B. Interestingly,
mTOR inhibition does not delay cells in the expansion phase
(Colombetti et al., 2006).
Canonically there are three E2F isoforms which promote
proliferation, E2F1-3, and that activation of these transcription
factors are essential to cell cycle progression (Wu et al., 2001).
However, it has been shown that in CD8+ T cells, E2F1-
3 can have both positive and negative effects on cell cycle
progression. Single knockout of either E2F1 or E2F2 results in
reduction in proliferation, while a double knockout yields a
hyperproliferative phenotype and reduced antigenic threshold
(Murga et al., 2001; Zhu et al., 2001). In addition to this,
CD8+ T cells deficient in E2F1 show much reduced activation
induced cell death (Gao et al., 2004). CD8+ T cells are not
the only cell line in which E2F behaves in a non-canonical
fashion. In retinal cells Myc mediated proliferation has been
shown to persist even in the absence of E2F1–3 proving these
E2Fs to be largely non-essential for these cells (Chen et al.,
2009), while in progenitor cell lines approaching terminal
differentiation, E2F1-3 seem to have a cell cycle repressive
role upon forming a complex with Rb (Chong et al., 2009).
It is, however, difficult to say whether similar processes are
occurring within CD8+ T cells post activation as the precise
molecular regulators of E2F transcription targets have yet to
be fully explored.
mTOR also upregulates the c-Myc transcription factor, which
has a crucial role in T cell metabolism (Vartanian et al., 2011;
Wang et al., 2011; Waickman and Powell, 2012) and expression
of several cell cycle regulators, including p27, cyclins, and CDKs
(Dang et al., 2006). T cells lacking c-Myc have defects in
glycolysis, glutaminolysis, cell growth, and proliferation. Indeed,
compared to wild type, c-Myc knockout cells show decreased
levels of CDK4, CDK2, and Cdc25A (Wang et al., 2011).
Furthermore, Raptor deficient cells that have impaired mTORC1
activity show reduced levels of key transcription factors including
Myc, but also GA-binding protein alpha chain (Gabpa), yin yang
(YY)1, and Sterol Regulatory Element Binding Transcription
Factor (Srebf)1, all of which are associated with mitochondrial
function (Tan et al., 2017).
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Cyclin-Dependent Kinase Regulation of
T Cell Activation
CDKi proteins interfere with the pathways downstream of TCR
stimulation. p27 is a key negative regulator of IL-2 production
in anergic CD4+ T cells (Boussiotis et al., 2000). Ectopic
expression of p27, but not p21, suppresses IL-2 production in
CD4+ T cells. Depletion of p27 in stimulated Jurkat T cells
enhances transcription of an IL-2 luciferase reporter construct
and enhanced cellular AP-1 activity. The proposed mechanism
is that p27 directly binds JAB1/COPS5, a subunit of the COP9
signalosome and positive regulates AP-1, inducing translocation
of AP-1 from the nucleus to the cytoplasm (Tomoda et al.,
1999), thereby suppressing IL-2 transcription (Boussiotis et al.,
2000). Whether this effect extends to CD8+ T cells is yet
to be determined.
There is significant interest in the roles of CDK4/6 in
immunomodulation, and how small molecule inhibitors of
CDK4/6 affect immune cell phenotypes. Recent data using
CDK4/6 inhibitors (CDK4/6i) suggest a direct role of Cyclin-
CDKs in controlling T cell differentiation. Three CDK4/6i
are FDA-approved for HR+ breast cancer: palbociclib (PD-
0332991), abemaciclib (LY2835219), and ribociclib (LEE011).
Numerous clinical trials are ongoing for the treatment of
other solid tumours (Álvarez-Fernández and Malumbres, 2020).
Extensive reviews on this topic already exist and lie outside the
scope of this review (Chaikovsky and Sage, 2018; Ameratunga
et al., 2019). Interestingly, recent evidence suggests these
inhibitors function similarly to the INK4 family of proteins by
binding to monomeric CDK4/6 (Guiley et al., 2019). Proliferation
of CD4+ Treg cells is inhibited by CDK4/6 inhibition whereas
proliferation of CD8+ cells is relatively unaffected (Goel et al.,
2017). Indeed, CD8+ T cell function can be augmented by
CDK4/6 inhibition. Treatment of CD8+ T cells with CDK4/6
inhibitors enhances NFAT activity, increasing expression of
CD25 and production of IL-2 and granzyme B, indicating that
CDK6 may have a role in limiting T cell effector differentiation
(Deng et al., 2018). Indeed, loss of CDK6 in T cells led to an
increase in IL-2 production, and was also seen to impair type
I interferon signalling events and increased metabolic processes
resulting in enhanced ATP production and maximal respiration
in addition to affecting proliferation (Klein et al., 2021).
In summary, T cell activation produces a signalling cascade
that triggers a change in gene expression that promotes cell
growth, increased anabolic metabolism, and stimulation of
nascent CDK/E2F activities. The significant rewiring of the
proteome and metabolism is important for supporting the next
phase of CD8+ T cell differentiation, in which activated cells
rapidly proliferate to clonally expand antigen-specific CTLs.
EXPANSION PHASE (IL-2 DRIVEN
PROLIFERATION)
A key regulator of CD8+ T cell proliferation in the expansion
phase is IL-2, a cytokine and potent T cell mitogen
(Smith and Ruscetti, 1981) that is produced primarily by
activated CD4+ and CD8+ T cells (Nelson, 2004). Upon
activation, CD8+ T cells secrete IL-2 and express a high affinity
IL-2 receptor subunit, CD25. Blockade of IL-2 leads to reduced
proliferation (Mishima et al., 2017). While TCR stimulation
alone has been shown to be sufficient to induce proliferation of
CD8+ T cells, the absence of IL-2 signal results in suboptimal
expansion and cell cycle slower progression (D’Souza and
Lefrançois, 2003). In addition, the presence of IL-2 in culture
reduces the minimum threshold of TCR signalling required to
enter cell cycle (Au-Yeung et al., 2017).
Continuous exposure to IL-2 is essential for prolonged
expansion. IL-2 starvation leads to reduced cell viability, loss
of CD25 expression, and decreased cellular protein content,
including many major cell cycle regulators: cyclin D2, cyclin D3,
cyclin A, cyclin B1, cyclin B2, CDK4, CDK6, CDK1, p15, and
p21. Notably, p27 is one of the few proteins to increase as a
result of IL-2 starvation (Rollings et al., 2018). p27 is implicated
in controlling cell cycle exit in the contraction phase. In vivo
experiments utilising p27 KO CD8+ T cells continued to expand
up to day 11 post immunisation, while WT began contraction
by day 8. The effect of p27 is more pronounced for MPECs
than SLECs. MPEC cells maintained their higher populations as
late as 30 days post immunisation, while SLEC p27 knockouts
generally returned to similar cell numbers as WT cells by day
15. This difference in response is likely due to MPECs expressing
higher pro-survival factors and having a greater capacity for IL-2
production than SLECs (Singh et al., 2010).
Whereas studies consistently show that p27−/− mice exhibit
splenic and thymic hyperplasia (Fero et al., 1996; Kiyokawa et al.,
1996; Nakayama et al., 1996), the data for p21−/− mice are
conflicting (Balomenos et al., 2000). Activated p21−/−, p27−/−
double knockout (DKO) splenocytes are hyperproliferative
in vitro. Freshly isolated splenocytes from p21−/− but not
p27−/− mice, had a higher frequency of CD25 expressing naïve
CD4+ and CD8+ T cells. The percentage of CD25+ cells in
activated DKO or p27−/− splenocyte cultures were elevated by
∼10% relative to wild type, or to p21−/− (Wolfraim et al.,
2004), which may enhance T cell sensitivity to IL-2, and therefore
mitogen-induced proliferation.
Downstream of IL-2 receptor activation is the STAT5 pathway
(Moriggl et al., 1999a), which is known to positively regulate
proliferation. STAT5 activation induces homeostatic proliferation
in naïve CD8+ T cells, even in the absence of cytokine stimulation
(Burchill et al., 2003), and in activated T cells, like mTOR,
STAT5 enhances E2F activity by activating S6K (Lockyer et al.,
2007). STAT5 KO T cells have reduced cell cycle regulators,
including cyclin D2, cyclin D3, cyclin E, cyclin A, and CDK6
(Moriggl et al., 1999b) while inhibition of STAT5 results in
a dose dependent loss of Cyclin E (Lai et al., 2009). All of
these proteins play important roles in G1-S phase progression.
STAT5 signalling upregulates levels of pro-survival proteins Bcl-
2 and Bcl-XL. Additionally, STAT5 upregulates c-Myc, further
implicating it as an important mediator of CD8+ T cell
proliferation (Lord et al., 2000). Constitutively active STAT5
promotes homeostatic proliferation and survival of CD8+ T
cells. Interestingly, STAT5 also enhances presence of T memory
cell phenotype, increasing the frequency of cells expressing key
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FIGURE 3 | Biochemical pathway analysis of cell cycle entry in murine CD8+ T cells with protein copies measured by quantitative proteomics. Four populations were
presented: (A) quiescent naive, (B) activation phase, (C) expansion phase toward SLEC phenotype, or (D) expansion phase toward MPEC phenotype. Numbers
indicate copy number of each protein as determined by quantitative proteomics, acquired from Immpress (“ImmPRes.co.uk,” University of Dundee). For protein
families (e.g., INK4, CIP/KIP, cyclins, and CDKs), summed copies are shown. E2F copies represent the sum of E2Fs 1–3. Median subunit copy number is shown for
the APC/C. Mechanisms predicted to be dominant are highlighted in bold lines, whereas suppressed pathways are indicated by dotted lines. P, phosphorylation;
U, ubiquitination.
memory markers including CD127, CD122, CD62L, and Bcl-2
(Hand et al., 2010).
As previously noted, CDK4/6 inhibitors are shown to enhance
CD25 expression during activation. However, post expansion
phase, cells that have been previously exposed to the inhibitors
produce a greater pool of memory T cells by upregulating Max
Dimerization Protein (Mxd)4, a negative regulator of Myc/Max
formation (Heckler et al., 2021). Interestingly, this event seems
to be independent of cell cycle arrest, suggesting a role for
CDK4/6 in affecting T cell development (Heckler et al., 2021;
Lelliott et al., 2021).
mTOR is also upregulated by IL-2 via the PI3K/AKT
pathway. However, other pathways contribute more strongly
to T cell proliferation in the expansion phase, as inhibiting
mTOR in this phase does not arrest proliferation (Howden
et al., 2019). Similarly, naïve CD8+ treated with AKT inhibitors
responded less to stimulation, with proliferation severely reduced
by day 2 of the culture in a dose dependent manner (Cho
et al., 2013). If treated 3 days post activation, however,
AKT inhibition resulted in little impact on proliferation
(Macintyre et al., 2011).
Conversely, T cells expressing constitutively activated AKT
were defective in memory T cell development in vivo. These
cells have reduced CD127, CD122, CD62L, and Bcl-2 (Hand
et al., 2010). CD127 reduction is predominately controlled by
PI3K/AKT activity in a STAT5 independent way, as STAT5
knockout cells had little impact on CD127 (Xue et al., 2002).
Constitutively active AKT cells also showed poor STAT5
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phosphorylation in response to any cytokine stimulation, and as
a result had a defect in homeostatic proliferation.
Taken together, these data suggest that a principal role of
the IL2R/PI3K/AKT/mTOR pathway is the differentiation of T
cells toward the SLEC phenotype, which occurs in parallel to
IL2R/STAT5. The latter is the dominant pathway that promotes
upregulation of cell cycle regulatory proteins and therefore
proliferation of CD8+ T cells.
Cyclin E/A-CDK2 complexes phosphorylate numerous
substrates, including targets outside of canonical cell cycle
pathways that directly regulate DNA replication and mitosis.
For example, cyclin E/A-CDK2 phosphorylates and inhibits
Foxo1 within a number of cancer cell lines (Huang et al.,
2006). In T cells, mTOR drives differentiation toward SLEC
phenotype by phosphorylation of Foxo1, an inhibitor of SLEC
phenotype transcription factor T-box expressed in T cells (T-bet)
(Rao et al., 2010; Michelini et al., 2013; Pollizzi et al., 2015).
Thus, CDK2-mediated inhibition of Foxo1 raises the intriguing
possibility that CDK2 may also have a role in enhancing T-bet
activity, and thus provide a mechanism by which high CDK2
expression can enhance differentiation. However, this has yet to
be demonstrated in T cells.
THE CELL CYCLE CONTROL PROTEIN
NETWORK IN T CELLS
T cell activation and their differentiation into effector and
memory cells provides exemplar systems to study the G0 to
G1 transition in non-immortalised cells in the physiological
context of the adaptive immune response. The proteomes of
these cells have been characterised to high depth using mass
spectrometry-based proteomics, enabling detailed measurements
of protein copies per cell in naïve and activated murine CD8+
T cells (Howden et al., 2019; Marchingo et al., 2020). The
Immunological Proteomic Resource (ImmPRes) is an open access
public resource consolidating proteomics experiments carried
out on murine immune cell populations, including effector and
memory CD8+ T cell states.1 We therefore used these publicly
available data to evaluate the copies of key cell cycle proteins
in naïve, activated (24 h), CTL (IL-2), and memory (IL-15) cell
populations (Figure 3).
These data show that naïve cells have proportionally higher
numbers of CDKis for each CDK (CIP/KIP and INK4) and very
low abundance of cyclins. For example, naïve cells express 3,800
copies of p27 and less than 1,000 copies each of cyclin D2 and
cyclin D3. In addition, levels of activating E2F transcription
factors (20 copies) are two orders of magnitude lower than
their stoichiometric inhibitor, Rb (1,400 copies). E2F activity
is therefore strongly inhibited, which maintains naïve cells in
quiescence. Interestingly, of the CIP/KIP family of proteins,
p27 is higher expressed than p21 except during IL-2 mediated
expansion, supporting a role of p27 over p21 as a regulator of
quiescence and homeostatic proliferation in T cells.
1http://www.immpres.co.uk/
Upon activation, E2F levels increase 500-fold to 14,000 copies,
contributing to a gene expression programme that promotes
G1/S progression. For example, levels of CDK1/2/4/6, cyclin D,
cyclin E, and cyclin A are all upregulated. Intriguingly, while
Rb levels increase in activated T cells to 7,800 copies. There
is a 3-fold increase in cyclin D2, and 8-fold increase in cyclin
D3, and around a 30-fold increase in CDK4/6 copies, while p27
decreases 19-fold. Interestingly, CD8+ T cells can bypass CDK4/6
inhibition (Goel et al., 2017), leading to slowed proliferation
(Heckler et al., 2021; Lelliott et al., 2021), but not arrest. The
major changes observed copies in the Rb-E2F pathway may
contribute to this resistance to G1 arrest by CDK4/6 inhibitors.
Inactivation of the APC/C is another mechanism to promote
G1/S transition (Cappell et al., 2018). Median copies of the
core APC/C subunits increase from 3,500 copies in naïve to
33,000 copies in activated T cells. Interestingly, Cdh1, the co-
activator and substrate adaptor subunit of APC/C during G1,
is undetectable in naïve and activated T cells. Likewise, Emi1 is
undetectable in naïve. However, Emi1, an E2F target, increases to
8,600 copies in activated T cells.
Interleukin-2-mediated differentiation into CTLs is
accompanied by a nearly 10-fold increase in Rb levels relative
to 24 h activated T cells. Unlike newly activated T cells, which
have nearly 2-fold excess E2F to Rb, CTLs contain far higher
copies of Rb (66,000) to E2F (10,000). Thus, in CTLs there are
sufficient levels of Rb, when not phosphorylated by CDK, to
suppress all copies of E2F. However, copies of cyclins and CDKs
are much higher in CTLs, leading to high activity of CDKs, which
phosphorylate and inactivate Rb. These two mechanisms of
E2F activation, Rb phosphorylation and excess E2F, suggest that
newly activated T cells and CTLs may have differential sensitivity
to pharmacological inhibition of CDK2/4/6.
Memory T cells produced by culture with IL-15 proliferate
slower. In contrast to CTLs, memory T cells have reduced levels of
cyclins and CDK2/4/6. However, like CTLs, copies of Rb (14,000)
exceed copies of E2F (2,200). This may make memory T cells
more sensitive toward Rb-mediated inhibition of E2F activity
compared to naïve and 24-activated T cells. Memory T cells
have increased copies of APC-C/Cdh1 (3,600) compared to CTLs,
which also may contribute to extending G1 phase by keeping
cyclin levels low.
CONCLUDING REMARKS
Immune cells play critical roles in normal physiology, pathology,
and the development of new therapies to treat disease.
Understanding fundamental mechanisms for how proliferation
is controlled in T cells will be important in making advances
in these areas of immunological research. This is highlighted
by recent studies showing that CDK4/6 inhibitors affect
proliferation of CD4+ Treg cells, but not CTLs (Goel et al., 2017),
and enhance functions of checkpoint-activated CD8+ T cells
(Deng et al., 2018). These results suggest that there are major
differences between CD4+ and CD8+ T cells in G1 control,
which will be interesting to explore in future studies. Deeper
insights into how the cell cycle control network is structured
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in different immune subsets may provide important clues into
the mode of action of these inhibitors on immune cells and an
opportunity to identify new targets for modulating immune cell
proliferation and function.
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